Amarin’s Vascepa received priority review status from the Food and Drug Administration for preventing cardiovascular events. Vascepa is an omega-3 drug approved for lowering triglycerides that can cause cardiovascular problems. A decision on the marketing application will be made September 28. (CNBC)

An overdose victim’s father testified on Wednesday in the Oklahoma opioid trial against Johnson & Johnson. The father stated that he was unaware until after his son’s death that his son was prescribed painkillers and had been abusing them. The state alleges J&J helped fuel the opioid epidemic with its marketing tactics. (Reuters)

W2O received a new private equity investment from New Mountain Capital. The firm is replacing W2O’s former investment firm Mountaingate Capital. Financial details were not disclosed. (MM&M)

Purdue Pharma’s international firm Munipharma is involved in a corruption case in Italy. Police allege a doctor, Dr. Guido Fanelli, took kickbacks from pharma execs, including Mundipharma. He was caught discussing how he made millions from over-prescribing painkillers. (AP News)

Seniors are spending more on cancer drugs than they did a decade ago, according to a study by The Journal of the American Medical Association. Although the Affordable Care Act helped lower costs, increasing drug prices have resulted in higher spending. For example, Revlimid, a treatment for multiple myeloma, has increased in cost by $4,000 since 2010. (Axios)